NVentures is NVIDIA’s venture capital arm, investing in companies across AI infrastructure and applications. Its portfolio includes businesses working on healthcare, software creation and computer-using agents, connecting the underlying AI technology stack with products built for specific tasks and industries.
Abridge, Lovable and Simular target different users and interfaces. Taken together, they illustrate how AI adoption depends on turning model capability into usable systems, with attention to deployment, interaction and task completion.
NVIDIA’s official NVentures materials discuss technical resources and long-term partnerships. The value of those resources depends on a company’s workloads and needs; investment alone should not be treated as proof of a special compute allocation or exclusive supplier relationship.
A transaction naming NVIDIA is not automatically an NVentures transaction. Corporate investments, commercial relationships and the venture arm’s disclosed portfolio can overlap, but each source must establish which entity it actually names.
Selected disclosed relationships, reviewed November 4, 2026. Each source supports the investment relationship; this is not a complete portfolio or a statement of current holdings.
Listed in NVentures’ official portfolio under healthcare and digital biology.
Source
Included in the venture arm’s curated portfolio on its official site.
Source
The company’s financing announcement explicitly names NVentures as a participant.
SourceNo. A financing announcement may identify NVIDIA at the corporate level, NVentures specifically, or both. The name used in the source determines the attribution. This profile includes relationships supported by NVentures portfolio materials or an explicit company announcement, rather than assigning every NVIDIA transaction to the venture arm.
An investment does not by itself disclose a hardware allocation, price or delivery commitment. NVIDIA describes technical expertise and resources as part of its venture offering, but commercial terms must be established separately. A startup’s compute strategy also depends on workload design, deployment environment and available infrastructure.
Clinical applications can require demanding speech, language and inference systems while also facing strict workflow and reliability constraints. That creates a connection to computing expertise without making healthcare adoption a hardware problem alone. Abridge’s portfolio inclusion is relevant to this intersection; it does not establish any particular purchasing commitment.
Computer-using agents interact with application interfaces and operating environments to complete tasks. Coding agents focus on producing or modifying software. Their activities can overlap, but evaluation differs: interface state, permissions and successful execution matter for computer use, while code correctness and maintainability are central to software development.
No. An ecosystem or startup-support program is a different relationship from an equity or other financial investment. Participation, technical collaboration and funding should be tracked separately. A disclosed NVentures portfolio entry or a financing announcement is needed before describing a company as an NVentures investment.
A founder should consider how NVIDIA’s technical ecosystem fits the startup’s workloads and future partners. That context can be relevant without implying any special commercial terms. Information rights, supplier flexibility and responsibilities for technical collaboration need to be assessed from the actual arrangements rather than assumed from the investment alone.